巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Marinus Pharmaceuticals

    MRNS
    5.340
    0.030
    0.56%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Marinus Pharmaceuticals - 延遲價格・最後更新於 20/05 12:15
    最高位
    5.800
    最低位
    5.150
    開市價
    --
    前收市價
    5.370
    成交量(千)
    23.74
    成交額(百萬)
    1.20
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    198.33
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    19.830 - 4.190
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Marinus Pharmaceuticals
    證券代碼
    MRNS.US
    所屬板塊
    Biotechnology
    公司業務
    Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
    發行量
    36771108
    公司總部
    100 Matsonford Road, Suite 500, 5 Radnor Corporate Center
    公司網址
    https://www.marinuspharma.com
    公司電郵
    sdamouni@marinuspharma.com
    公司電話
    +1 484 801-4670

    美股異動 | Marinus製藥(MRNS.US)跌11.85% 第四季度虧損擴大 收入遠低於預期

    格隆匯·
    美股異動 | Marinus製藥(MRNS.US)跌11.85% 第四季度虧損擴大 收入遠低於預期

    美股異動 | Marinus製藥(MRNS.US)跌11.85% 第四季度虧損擴大 收入遠低於預期

    格隆匯·
    美股異動 | Marinus製藥(MRNS.US)跌11.85% 第四季度虧損擴大 收入遠低於預期

    關於

    Marinus Pharmaceuticals(MRNS.US)所屬的行業板塊為Biotechnology。
    Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
    詳細公司背景可參考: https://www.marinuspharma.com